NIKKEI 225
38,781.28 -141.72 (-0.36%) HANG SENG
18,470.36 +67.36 (+0.37%) CRUDE OIL
73.30 -0.92 (-1.24%) GOLD FUTURES
2,368.60 -0.70 (-0.03%) DOW
38,571.03 -115.27 (-0.30%) Bitcoin GBP
53,907.07 +270.25 (+0.50%)
MRK Jan 2026 90.000 call
| Previous close | 45.33 |
| Open | 45.40 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 90.00 |
| Expiry date | 2026-01-16 |
| Day's range | 45.33 - 45.40 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
Simply Wall St.Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
BenzingaSummit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
